Nyxoah SA (NYXH) stock
NYXHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.86−0.04 (-4.10%)
Close on Nov 18, 2026Market cap $37.13MP/E –Yield –
Nyxoah r&d expenses
Research and development expenses are spending on new products and technology.
Nyxoah's R&D Expenses for the twelve months ending Dec 31, 2022 was €15.86M, up 28.5% year over year. For fiscal 2025 it was €42.82M, up 24.8% from the year before. The highest annual figure on record is €42.82M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €42.82M | +24.8% |
| FY2024 | Dec 31, 2024 | €34.33M | +28.8% |
| FY2023 | Dec 31, 2023 | €26.65M | +68.0% |
| FY2022 | Dec 31, 2022 | €15.86M | +28.5% |
| FY2021 | Dec 31, 2021 | €12.34M | +428.4% |
| FY2020 | Dec 31, 2020 | €2.34M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €9.54M | +108.6% |
| Q2 FY2025 | Jun 30, 2025 | €10.06M | +138.3% |
| Q2 FY2024 | Jun 30, 2024 | €7.47M | +115.3% |
| Q2 FY2023 | Jun 30, 2023 | €6.61M | +98.1% |
| Q4 FY2022 | Dec 31, 2022 | €4.58M | +30.1% |
| Q3 FY2022 | Sep 30, 2022 | €4.22M | – |
| Q2 FY2022 | Jun 30, 2022 | €3.47M | – |
| Q4 FY2021 | Dec 31, 2021 | €3.34M | – |
| Q3 FY2021 | Sep 30, 2021 | €3.52M | – |
See a number that looks wrong?